WyBioLogics and HK Innoen Complete Patent Application for Jointly Developed HLA-G Antibody
[Asia Economy Reporter Lee Gwan-joo] Y-Biologics announced on the 14th that it has completed a domestic patent application for the immune-oncology candidate HLA-G monoclonal antibody, which it has been jointly researching with HK Innoen.
HLA-G is an immune checkpoint protein expressed in various cancer types and is attracting attention as an alternative target for tumors that show little response to existing anti-PD-(L)1 inhibitors.
HK Innoen plans to expand follow-up research to develop not only antibody therapeutics but also CAR-T and CAR-NK cell therapies using the HLA-G antibody developed through joint research with Y-Biologics. Y-Biologics aims to continue developing next-generation bispecific antibody immune-oncology drugs that simultaneously target HLA-G and the CD3 of T cells.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Y-Biologics explained, “By developing therapeutics that meet the demand for new immune-oncology biomarkers, we expect to improve treatment efficacy even in solid tumors,” adding, “This will replace the unmet needs caused by low survival rates, side effects, and non-responsiveness of existing chemotherapy and targeted cancer therapies.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
